Bayer AGBayer AG will recover after ending in a last wave 5 of C. On the right side mentioned all the former gaps.
BAYRY trade ideas
BAYER AG: $40.60 | Aspirin AlkaSeltzer Monsanto + $11bn Settled Bill Anderson doing the roadshow in Dc and Carlyle Group seems to be
going in heavy at current levels or lower for the next RUN UP
a long game to make a killing for heavy hitters in the pharma bio agri chemical business
the timing to position for such a deal takes time and feel in the this type of business
the usual play is Dress up Window PUMP for public retails the rest to participate
unload shares and reserve cash to acquire a highly controversial company MONSANTO
ROUNUP herbicide with Glycophaste is the EYE SOAR or hang up where litigation is a downgrade for fund managers
it settled the 100,000 lawsuits on roundup to $11bn just this October 2023
this is done.. and we begin to DCA slowly and reserve at the buy zone or shakedown levels
for next WINDOW DRESSING acquisition of BAYER
could be a COViD Vaccine or some super food enhance in the VEGiE MEAT business gaining traction
Bayer (BAYN): End of a long 9-year correctionBayer (BAYN): XETR:BAYN
Upon request from one of our members, we're taking a closer look at Bayer AG. We believe that we are still in an overarching Wave II. This wave finds its last true support at the 88.2% retracement level at €24.51. Falling significantly below this level would likely lead us to see a 100% retracement down to €8.48, which would be severe for a company like Bayer, considering its all-time high was at €144. Observing the chart on a 2-day basis, we note that the Wave 5 extension falls into the zone between 50% and 61.8%, which also includes the 88.2% level. This truly is the last turning point Bayer might have.
Bayer (BAYN): Is the Bottom Finally Here?Since our initial analysis in November, Bayer's stock has experienced a 40% pullback. Despite missing our limit order by 2%, we have decided to enter the market now and plan to make additional purchases if the price drops further.
The stock has held around the 88.2% Fibonacci retracement level. We are currently within the 50-61.8% Fibonacci extension zone for Wave 5, which aligns with our bottom outlook.
Our entry strategy involves making an initial purchase now, acknowledging the recent support levels. We plan to add to our position with multiple entries if the price drops further. Our stop-loss is set wide, at an additional 44% below our entry price, to accommodate potential volatility. This is considered a long-term swing trade, with an expectation of significant upward movement once the bottom is confirmed. This could be a knife catch here so please don't cut yourself too deep.
GERMANY STOCK > ( BAYN ) long Based on my graphic analysis I observe a bullish projection of 11% in the price of this corporation, that is; from $28.79 it will rise to $31.96. With a sell exit emerging at $26.47, it is worth remembering that exactly how long the rally will take is unpredictable, the market will simply do its job. We can mention that it will happen within the next 15 to 25 days from this post!
REFERENCES:
* Green line: purchase price: $29.79
* Red line: emerging exit (stop loss) -8%
* White goods: profit +11%
However, it is important to remember that these marked lines must be respected. If the price drops 3-5% after executing the position, don't try to improvise and change everything. The movement could return to the initial direction and you will be left frustrated!
"Sitting calmly and waiting for the development of the operation most of the time will allow you to earn much more money. That is, sit in the stands and enjoy the spectacle that the bull will present to you, control your emotions, since "The biggest enemy to "The time to invest is yourself."
As for capital management, I leave it to personal discretion knowing that we must always have money flowing and remain firm in the market.
Greetings and I hope you take advantage of this good negotiation opportunity!
> Josías Baltazar.n
Bayer double bottom Bayer was trending down for last almost a year. Now it's seems to draw the double botton. Stock found the support, bounce twice and seems to be recovering. Moreover, the dividend is incomingin near future what could boost the price additionally.
this is not a recomendation, only my guess what could happen
If Germany is the sick man of Europe. #Bayer looking deathlyThe #EU is Marxist, Socialist, and is involved in Price setting
That didn't work out too well for USSR as economic powerhouse
and so too we see the once great German economy being brought to it's knees.
It is being de-industralized and being brought down in a great economic levelling of the union
Such a shame
Bayer Pharmaceutical is arguably a company we could do without .. so this chart does not upset me too much ...
But it is major component of the #DAX and highlights the economic pain that Germany may indeed go through in the next recession.
Bayer Cuts Dividends to Reduce DebtIn a strategic move to tackle its mounting debt and enhance financial flexibility, Bayer ( OTC:BAYRY ), the German pharmaceutical giant, has announced a significant shift in its dividend policy. The decision, though met with mixed reactions from investors and analysts, underscores the company's commitment to addressing its pressing financial challenges.
Facing High Debt and Challenging Cash Flow:
Bayer's ( OTC:BAYRY ) decision to amend its dividend policy stems from a pressing need to mitigate its high debt burden and grapple with a challenging free cash flow situation. Chief Executive Bill Anderson emphasized the company's priority to reduce debt and increase flexibility, acknowledging the necessity of the amended dividend policy in achieving these objectives.
A Drastic Reduction in Dividends:
The scale of the dividend reduction is striking. From 2.40 euros per share in the previous year, Bayer ( OTC:BAYRY ) now proposes a mere 0.11 euro dividend for 2023. This substantial cut reflects the severity of the financial constraints Bayer is contending with and underscores the urgency with which it seeks to address them.
Analyst Insights and Investor Reactions:
Analysts at Jefferies have characterized Bayer's move as emblematic of the extensive operational and financial challenges confronting the company. They emphasize the need for further significant strategic actions to rectify the balance sheet and restore investor confidence. Investor reactions have been mixed, with some expressing understanding of the company's predicament, while others voice concerns about the implications for shareholder returns and the long-term health of the business.
Strategic Imperatives: Job Cuts and Potential Breakup:
Bayer's ( OTC:BAYRY ) dividend policy amendment follows a series of strategic maneuvers aimed at stabilizing its financial position and reigniting growth. In January, the company announced job cuts, signaling a commitment to streamline operations and reduce costs. Moreover, Bayer ( OTC:BAYRY ) has been exploring options to potentially dismantle its diverse portfolio, which includes prescription drugs, consumer health products, crop chemicals, and seeds. This strategic evaluation underscores the company's willingness to undertake bold measures to revitalize its performance and buoy its beleaguered share price.
Conclusion:
Bayer's ( OTC:BAYRY ) decision to revise its dividend policy represents a pivotal moment in its ongoing efforts to navigate choppy financial waters. As the company grapples with high debt, challenging cash flow dynamics, and analyst scrutiny, its strategic imperatives underscore a commitment to reshaping its business for sustained success. The road ahead may be fraught with challenges, but Bayer's ( OTC:BAYRY ) willingness to confront them head-on signals a determination to emerge stronger and more resilient in the face of adversity.
Buy Bayer AG Scalp and HOLDHello, here my IDEA for BAYER AG, a big player in Germany
and WORLDWIDE. Make 3 Position and take the Profits, for Longtime
Investors BUY and HOLD.
BAYN: Potential BuyRetesting the channel price recently broke out of, this represents a possible buy opportunity backed with a recent insider buying activity. First target right after the gap where you could take partials, then 48 EUR. If you believe in the company why not hold to ATH.
BAYN Entry ZoneBayer has reached a Fibonacci entry zone after yesterday's fall.
There is a window to be closed that has been opened at the fall on November 20th.
Bayer: Down the hatch! 🍺After Bayer's stock recently tried to break through the support level of €39.91, it has now made another attempt. Whether the stock succeeds in sustainably breaking below this support level - as envisaged in our primary scenario - or whether it needs further impetus in the form of a corrective upward move is irrelevant for the further course of our expectations. We therefore fully expect a sell-off below this level, as we expect the low of the major wave (II) correction underway since 2015 to be around the 78.60 retracement at €30.84. Only once this low is in place do we see Bayer shares making sustainable gains again.
Why Bayer Stock is a Great Long-Term Investment OpportunityBayer AG is a German multinational pharmaceutical and life sciences company founded in 1863. The company is headquartered in Leverkusen, Germany, and employs over 100,000 people worldwide. Bayer's core business areas are human and veterinary pharmaceuticals, consumer healthcare products, agricultural chemicals, and biotechnology products.
Bayer stock is a great long-term investment opportunity for several reasons. The first one is that its stock has created a strong weekly demand level located at around 49 euros per share. This should be enough reason to buy Bayer AG stock shares. Secondly, the company has a strong history of financial stability and profitability. In addition, Bayer has a diversified product portfolio with exposure to many different industries. Bayer is committed to innovation and has a strong R&D pipeline.
Bayer AG is a publicly traded company with shares that trade on the Frankfurt Stock Exchange, and the company has a market capitalization of over €51 billion. The company's stock has not performed well in recent years, losing more than 70% of its value since up more than 50% since 2016. It's now a great opportunity to buy shares of Bayer AG stock. There is a lot of profit potential with room to reach €88 per share and higher.
Bayer AG (BAYN.de) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the German company Bayer AG (BAYN.de). Bayer AG is a German multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include pharmaceuticals; consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The Falling Wedge broke through the resistance line on 22/03/2023. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 9 days towards 60.750 EUR. According to experts, your stop-loss order should be placed at 54.890 EUR if you decide to enter this position.
Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive told Reuters.
Sebastian Guth, president of Bayer's pharmaceuticals business in the Americas, in an interview with Reuters, said the company increased U.S. employees working on marketing for its pharmaceutical business by around 50% over the last three years and plans to expand on that by another 75% by 2030.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals and cannot be held liable nor guarantee any profits or losses.
Long term playI see this a a company that I could potentially add to the portfolio I have been creating, it consists of assets that I will buy and hold for more than 15 years.
BAYN // Pennant formationWhile there is pennant formation on the chart, pay attention to the wedge resistance on the monthly time frame.
Bayer continues to hold back the bulls.Bayer AG - 30d expiry - We look to Sell at 54.48 (stop at 56.11)
Daily signals are bearish.
54.50 continues to hold back the bulls.
Bespoke resistance is located at 54.50.
Preferred trade is to sell into rallies.
The bearish engulfing candle on the daily chart is negative for sentiment.
Our profit targets will be 50.41 and 49.41
Resistance: 52.00 / 53.20 / 54.50
Support: 49.50 / 48.50 / 47.00
Disclaimer – Saxo Bank Group.
Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
#BAYN long ideaHello dear Traders,
Here is my idea for #BAYN
Price closed above yellow line (previous month high)
Price closed (15min Chart) above purple trigger line to enter trade.
Targets marked in the chart (black lines)
Invalidation level marked with red line
Good luck!
❤️Please feel free to ask any question in comments. I will try to answer all! Thank you.
Please, support my work with like, thank you!❤️
BAYN // moving averagefor bullish let's wait for it to cross yellow 20 avg.blue 50 avg up. Watch out for wedge indicator resistance on monthly timeframe.
Short-term buy until EUR 60 before falling down to EUR 40.The Elliott-Wave patter appears to be drawn on current Bayer 1h chart. Longterm, after reaching EUR 60 and going down and touching the 40 EUR area, I expect Bayer to recover and aim for its pre-Covid high of around 80 EUR. Fundamentally Bayer is undervalues, also when it comes to some new products that are in the process of being legalized.
longterm buy, short-term sell After the complete 1-5 Elliot-Wave and the correction wave Bayer is still not in an upward trend. Despite Bayer's technical improvement, the stock is still not in an upward trend, and lower lows are not excluded in the coming quarters.
Currently, it appears that Bayer is beginning to move higher, and €46 in October may have represented a bottom. Although we shouldn't get too excited yet, since Bayer isn't technically in an upward trend until the stock moves above the last high of €74 (June 2020) and, ideally, also above the pre-pandemic high of €78. As year is coming close to an end and macroeconomic situation is not at its best, I expect the a bottom touch of €40 before it goes longterm up in the spring of 2023.
Bayer AG at key supportBayer AG
Short Term
We look to Buy at 56.39 (stop at 54.46)
Trading within a Bullish Channel formation. The medium term bias is for higher levels but intraday signals are mixed. Previous support located at 56.00. Bullish divergence can be seen on the daily (the chart makes a lower low while the oscillator makes a higher low), often a signal of exhausted bearish momentum, or at least a correction higher. Further upside is expected although we prefer to set longs at our bespoke support levels at 56.00, resulting in improved risk/reward.
Our profit targets will be 61.39 and 65.99
Resistance: 66.00 / 70.00 / 110.00
Support: 56.00 / 50.00 / 43.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
BAYERN - GOLDEN CROSSUpward movement for the stock of Bayern in the last quarter. Has even scored a Golden cross
